Evidence map›Paper›PMID 40205882›Full record

ReviewTherapeutic delivery2025

The progress of hyaluronic acid's application in therapeutic delivery.

Flavia Laffleur, Katharina Bachleitner, Gioconda Millotti, Jennifer Lagast, Florina Veider, Andreas Bernkop-Schnürch

Abstract readReview
In one paragraph

Review in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A novel integratedRegenerative biomaterials · 2026
    Article
  2. Advances in hyaluronic acid hydrogel for meniscus repair.Frontiers in bioengineering and biotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Flavia LaffleurDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Katharina BachleitnerDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Gioconda MillottiFaculty for Natural Sciences, Juraj Dobrila University of Pula, Pula, Croatia.
Jennifer LagastDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Florina VeiderDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.
Andreas Bernkop-SchnürchDepartment of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyaluronic acid (HA) is a widely available, bio-compatible, polysaccharide with unique physical and chemical properties, which have inspired its application in many fields. Firstly, HA is a significant representative in wound healing, embryonic development, repair as well as regeneration. Secondly, HA exhibits pregnant meaning in cancer progression. Tumor cell proliferation, invasiveness, and motility can be modulated by the accumulation of HA in tumor stoma. Thirdly, HA is an actor in regulation processes during the angiogenesis. The level of HA, even low-molecular-weight HA, is considered to be a biomarker of tumor malignancy. Within this work, an intense overview of its application and the use of HA in drug delivery systems is given.HA plays a crucial role in many cases, such as cell signaling, morphogenesis, matrix organization, tissue regeneration, and pathobiology. Biocompatibility, mucoadhesivity, hygroscopicity, biodegradability, and viscoelasticity are to mention as physico-chemical properties of hyaluronan. This is why exogenous HA is investigated for drug delivery systems and exhibits a representative therapy of cancer, esthetic medicine, rhinology, arthrology, and cosmetics.In the end, the proof of concept presented by clinical trials is convincing to further investigate native HA as well as modified one for therapeutic delivery purposes.

Indexed as

Drug Delivery SystemsHyaluronic AcidAnimalsHumansNeoplasmsHyaluronic AcidCancer therapyhyaluronic acidliposomesnanoparticlesoral

Identifiers

PMID40205882
PMCPMC12266678

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.